Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 172
- Registration Number
- NCT06772623
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Lone Tree /ID# 272603, Lone Tree, Colorado, United States
🇺🇸Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 80
- Registration Number
- NCT06769971
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
- Conditions
- Advanced NSCLCAdvanced Endometrial Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT06758557
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06754930
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 464
- Registration Number
- NCT06754644
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
- Conditions
- Early or Locally Advanced HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT06747338
- Locations
- 🇨🇳
Clinical Trials Information Group, Shanghai, China
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 318
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 105
- Registration Number
- NCT06735326
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Radiation: Low-dose radiotherapyDrug: Tifcemalimab injection
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 12
- Registration Number
- NCT06732258
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06731907
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇬🇷European Interbalkan Medical Center-Oncology Department ( Site 0205), Thessaloniki, Greece
🇮🇱Rambam Health Care Campus ( Site 0076), Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.